We investigated the effects of levcromakalim, a K+ channel opener, on [Ca2+]i and the contractile force of basilar arteries obtained from normal dogs and subarachnoid hemorrhage (SAH) dogs. The responsiveness to serotonin was increased more in the SAH group than in the control group. Levcromakalim decreased the resting [Ca2+]i and force more profoundly than did a Ca2+ channel blocker, nicardipine, and these effects were more prominent in the SAH group than in the control group. Levcromakalim diminished the increases in [Ca2+]i and contractile force induced by serotonin more profoundly than nicardipine did, and these effects were equal in both groups. The effects of levcromakalim were not inhibited by iberiotoxin but were antagonized completely by glibenclamide. These results suggest that levcromakalim-induced opening of adenosine triphosphate (ATP)-sensitive K+ (K(ATP)) channels reduces [Ca2+]i more effectively than does nicardipine and that levcromakalim exerts the vasodilator effects under the condition in which large conductance Ca2+-activated K+ (BK) channels are blocked with iberiotoxin. Consequently, K+ channel openers like levcromakalim may be useful drug candidates to treat delayed cerebral vasospasm after SAH.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00005344-199906000-00006DOI Listing

Publication Analysis

Top Keywords

effects levcromakalim
8
[ca2+]i contractile
8
contractile force
8
sah group
8
group control
8
control group
8
group levcromakalim
8
nicardipine effects
8
levcromakalim
7
sah
5

Similar Publications

Human experimental studies have shown that levcromakalim, an ATP-sensitive potassium (K ATP ) channel opener, induces migraine attacks in people with migraine but not in healthy volunteers. However, the exact site of action for K ATP channels in migraine pathophysiology remains unclear. This study investigates the role of these channels in the meninges in eliciting behavioral hypersensitivity responses in mice.

View Article and Find Full Text PDF

Effects of levcromakalim in patients with migraine aura without headache: An experimental study.

Cephalalgia

August 2024

Danish Headache Center, Department of Neurology, Rigshospitalet - Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.

Background/hypothesis: Levcromakalim has previously been shown to induce attacks of migraine with aura in certain individuals. In this study, we tested the migraine-inducing effect of levcromakalim in a cohort of participants with migraine aura without headache.

Methods: In a double-blind, randomized, placebo-controlled cross-over study, eight adult participants with migraine with aura received intravenous infusions of levcromakalim and saline.

View Article and Find Full Text PDF

Extrasynaptic δGABAA receptors mediate resistance to migraine-like phenotype in rats.

J Headache Pain

May 2024

Department of Medical Pharmacology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, 06320, Türkiye.

Background: GABA, a key inhibitory neurotransmitter, has synaptic and extrasynaptic receptors on the postsynaptic neuron. Background GABA, which spills over from the synaptic cleft, acts on extrasynaptic delta subunit containing GABAA receptors. The role of extrasynaptic GABAergic input in migraine is unknown.

View Article and Find Full Text PDF

We tested five chemically and metabolically stable prostaglandin (PG) receptor agonists in a mouse model of dexamethasone-induced ocular hypertension (OHT). Whilst all compounds significantly ( < 0.05, ANOVA) lowered intraocular pressure (IOP) after twice-daily bilateral topical ocular dosing (5 µg/dose) over three weeks, the time course and magnitude of the responses varied.

View Article and Find Full Text PDF

Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura.

Cephalalgia

March 2024

Danish Headache Center, Department of Neurology, Rigshospitalet - Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

Article Synopsis
  • The study investigates the potential of levcromakalim to induce migraine attacks and migraines with aura, following previous findings that it can trigger such conditions.
  • In a controlled trial with 27 participants, those receiving levcromakalim were more likely to experience migraine-like attacks compared to those given a placebo, with a median onset of three hours for headaches.
  • While the migraine-inducing effects of levcromakalim were confirmed, the study found a lower rate of aura development than expected, suggesting a need for further research on factors predicting migraine aura.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!